secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hongchang International Co., Ltd (HCIL)
CIK:        0001086303
Form:       8-K
Filed at:   2023-09-07T23:59:59+00:00
Accession:  0001213900-23-074978
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 2.01, 3.02, 5.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Heyu Biological Technology acquires Hongchang Group in reverse merger, exits prior cancer therapy business
--------------------------------------------------------------------------------

- Acquired all shares of Hongchang BVI for 415.6M new shares (80.1% of post-acquisition total).
- Disposed of prior business (HP TECHNOLOGY, Jiashierle, Kangzi) to director Ban Siong Ang for nominal consideration.
- New business: Hongchang Food Industrial Park (under construction, completion expected 2024) in Fujian, China.
- Mr. Zengqiang Lin becomes controlling shareholder via Zengqiang Investment Limited (415.6M shares).
- Company now has 518.8M shares outstanding; new executive offices in Fuqing City, Fujian, China.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1086303/000121390023074978/0001213900-23-074978-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1086303/000121390023074978/ea183857-8k_heyubiologi.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-074978

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer